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Abstract
Human pathogens belonging to the Nakaseomyces clade include Candida glabrata sensu stricto, Candida nivariensis and
Candida bracarensis. Their highly similar phenotypic characteristics often lead to misidentification by conventional laboratory
methods. Therefore, limited information on the true epidemiology of the Candida glabrata species complex is available. Due to
life-threatening infections caused by these species, it is crucial to supplement this knowledge. The aim of the study was to
estimate the prevalence of C. bracarensis and C. nivariensis in a culture collection of C. glabrata complex isolates. The study
covered 353 isolates identified by biochemical methods asC. glabrata, collected from paediatric and adult patients hospitalised at
four medical centres in Southern Poland. The multiplex PCR was used to identify the strains. Further species confirmation was
performed via sequencing and matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS)
analysis. One isolate was recognised as C. bracarensis (0.28%). To our knowledge, it is the first isolate in Poland. C. glabrata
sensu stricto species has been confirmed for all the remaining isolates. NoC. nivariensiswas found. Our study has shown that the
prevalence ofC. nivariensis andC. bracarensis strains is infrequent. However, it should be emphasised that the incidence of these
strains may differ locally and depend on environmental factors and the population.
Introduction
Candida glabrata species complex, including Candida
glabrata sensu stricto, Candida nivariensis and Candida
bracarensis, are the only human pathogens belonging to the
Nakaseomyces clade (Gabaldón et al. 2013). The latter two
yeast species have been described for the first time about
10 years ago, but their clinical relevance is still to be deter-
mined (Alcoba-Flórez et al. 2005; Correia et al. 2006). Several
reports from different parts of the world indicate their associ-
ation with bloodstream infections, invasive and oral candidi-
asis, urinary tract infections and vulvovaginitis (Angoulvant
et al. 2016). A decreased susceptibility to some antifungal
agents, observed among the isolates, is particularly important
(Fujita et al. 2007; Borman et al. 2008). Although their path-
ogenicity has been well documented, the true epidemiology of
infections caused by species belonging to C. glabrata com-
plex is not yet fully understood. Due to little evidence for
phenotypic di ffe rences be tween C. nivar iens i s ,
C. bracarensis and C. glabrata, these species cannot be dis-
tinguished by conventional methods (Criseo et al. 2015). It is
one of the reasons why in the last years a number of molecular
methods have been developed to improve identification of
these microorganisms. While DNA sequencing of the fungal
rDNA ITS region is considered as the reference method for
confirmation of species identification, PCR-based assays, pro-
posed by some authors, have proved to be highly efficient in
the identification ofC. nivariensis andC. bracarensis (Romeo
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2013). The advantages of these methods are their simplicity,
time and cost-effectiveness, as well as accuracy, making them
suitable tools for investigating Candida epidemiology at a
local level.
The aim of the study was to estimate the prevalence of
C. bracarensis and C. nivariensis in a culture collection of
C. glabrata complex isolates, obtained from ambulatory and
hospitalised patients at four different medical centres in
Southern Poland, using the multiplex polymerase chain reac-
tion (PCR) method.
Material and methods
Strains collection and phenotypic identification
The study covered 353 yeast strains collected from paediatric
and adult patients (56 isolates; 15.9% and 297 isolates; 84.1%,
respectively) at four medical centres in Kraków, Poland, be-
tween 2009 and 2016.
Among the adult patients, most yeast strains were isolated
from the lower respiratory tract samples (endotracheal aspi-
rate, sputum, bronchoalveolar lavage fluid) (81; 27.3%), up-
per respiratory tract samples (49; 16.5%), stool specimens (47;
15.8%), vulvovaginal swabs (45; 15.2%), urine (35; 11.8%)
and blood (17; 5.7%). Isolates from children were obtained
mainly from stool samples (36; 64.3%), vulvovaginal swabs
(8; 14.3%) and urine (5; 8.9%). Antifungal susceptibility pat-
terns of the tested isolates did not differ from epidemiological
data reported in the literature, in which most of the isolates
were intermediately susceptible to fluconazole.
All isolates were identified as C. glabrata by routine my-
cological culture on Sabouraud dextrose agar supplemented
with chloramphenicol and biochemical testing, e.g. using
VITEK 2 Compact automated system (bioMérieux, Marcy
l’Etoile, France).
Multiplex PCR-based molecular identification
A total of 353 isolates were analysed by a multiplex PCR
assay described by Romeo et al. (2009) using primers
targeting the ITS1 region and the 5.8S ribosomal RNA gene.
Quality control of the assay was warranted by incorporating
reference strains of C. glabrata (ATCC 2001), C. nivariensis
(CBS 9983) and C. bracarensis (CBS 10154).
Candida bracarensis—confirmation of species
identification (phenotypic and molecular analysis
of the isolate)
The isolate identified as C. bracarensis by PCR analysis has
been subjected to further phenotypic characterisation, includ-
ing subculture on chromogenic media (CHROMagar
Candida, Becton Dickinson, Franklin Lakes, NJ, USA;
Candida Chromogenic LAB-AGAR ™, Biocorp, Warsaw,
Poland), evaluation of fermentation and assimilation proper-
ties as well as the ability to hydrolyse urea by API Candida
(bioMérieux, Marcy l’Etoile, France) and AUXAColor 2
(BioRad, Marnes-la-Coquette, France), and estimation of
morphological features by culture on a nutritionally poor me-
dium (rice extract agar) and incubation for 48 h at 27 °C.
Furthermore, MALDI-TOF MS identification using
MALDI Biotyper (Bruker Daltonics, Billerica, MA, USA)
was performed at the Jagiellonian Centre of Innovation
(Kraków, Poland). The analysis was conducted using the
IVD (in vitro diagnostic) database and scores ranging 2.00–
3.00 were considered as a high-confidence identification of a
microorganism to the species level.
Confirmation of species identification based on bi-
directional sequencing of the PCR product and comparison
of the consensus sequence with that of the C. bracarensis
CBS 10154 reference strain (GenBank accession number
GU1990440.1) was performed by Genomed (Warsaw,
Poland). Furthermore, we analysed the sequence similarity
using the BLASTn tool of the National Centre for
Biotechnology Information (NCBI) (ncbi.nlm.nih.gov/
BLAST/).
Susceptibility testing
In vitro susceptibility testing of the C. bracarensis isolate
against amphotericin B (AMB), fluconazole (FLC),
itraconazole (ITC), voriconazole (VRC), caspofungin (CS),
anidulafungin (AND) and flucytosine (5FC) was performed
using strips impregnated with antifungal agent gradient, E-
strips (AB BIODISK, Solna, Sweden and Liofilchem, Italy).




Based on the multiplex PCR assay targeting the ITS1 region
and the 5.8S ribosomal RNA gene, 352 isolates were identi-
fied as C. glabrata sensu stricto (99.7%) and one isolate
(SU3498) as C. bracarensis (0.3%) (Fig. 1). No
C. nivariensis were found.
Candida bracarensis—the isolate characterisation
(phenotypic and molecular analysis)
The SU3498 isolate was cultured from a stool sample obtain-
ed from a 32-year-old man hospitalised at the Department of
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Metabolic Diseases of the University Hospital in Kraków due
to peripheral neuropathy in type 1 diabetes in May 2016.
The SU3498 isolate produced small, white, shiny and
smooth colonies on the Sabouraud dextrose agar. On both
chromogenic media CHROMagar Candida (Becton
Dickinson, Franklin Lakes, NJ, USA) and Candida
Chromogenic LAB-AGAR TM (Biocorp, Warsaw, Poland),
it also formed white colonies (Fig. 2). The isolate produced
slow-growing colonies, better at 30 ± 2 °C than at 35 ± 2 °C,
and did not form either hyphae or pseudohyphae after incuba-
tion on rice extract agar.
The tested isolate fermented and assimilated glucose and
trehalose but did not hydrolyse urea.We observed the inability
of this isolate to assimilate maltose, sucrose, galactose,
lactose, raffinose, inositol, cellobiose, adonitol, melezitose,
xylose and arabinose.
Proteomic identification by the MALDI-TOF MS method
has confirmed that the SU3498 isolate belongs to the species
C. bracarensis with a score value of 2.1.
The consensus sequence of the PCR product (GenBank
accession number MH729062) showed 98% similarity to that
of C. bracarensis type strain CBS 10154 (GenBank accession
number GU1990440.1). The BLAST search of all available
nucleotide sequences revealed that this sequence was identical
to that of the C. bracarensis strain OAHPPFR1227 (GenBank
accession number JN882338.1) as well as uncultured fungus
clone CMH366 (GenBank accession number KF800457.1),
isolated from an environmental sample (Rittenour et al. 2014).
The SU3498 isolate has been deposited at the Polish
Collection of Microorganisms under the number PCM 2995.
Susceptibility testing
Antifungal susceptibility test results were as follows:
amphotericin B (MIC = 0.19 mg/L), flucytosine (MIC =
0.25 mg/L), fluconazole (MIC = 3 mg/L), voriconazole
(MIC = 0.125 mg/L), itraconazole (MIC ≥32 mg/L),
posaconazole (MIC ≥32 mg/L), anidulafungin (MIC =
0.004 mg/L) and caspofungin (MIC = 0.125 mg/L).
Discussion
Although more than 17 different species of Candida have
been reported to be pathogenic to humans, about of 90% of
invasive candidiasis are caused by five species—C. albicans,
C. glabrata, C. parapsilosis, C. tropicalis and C. krusei
(Pfaller and Diekema 2007). C. albicans remains the predom-
inant species recovered from clinical specimens worldwide.
However, in the last decades, non-albicans species have
Fig. 1 Multiplex PCR assay results of references strains and the clinical
isolate identified as C. bracarensis. Lines: 1, 7—marker; 2—C. glabrata
ATCC 2001; 3—C. nivariensis CBS 9983; 4—C. bracarensis CBS
10154; 5—clinical isolate SU3498; 6—negative control
Fig. 2 The appearance of
C. glabrata ATCC 2001,
C. nivariensis CBS 9983,
C. bracarensis CBS 10154 and
clinical isolate SU3498 after 48 h
of incubation at 35 °C on
CHROMagar Candida (Becton
Dickinson, Franklin Lakes, NJ,
USA) (a) and Candida
Chromogenic LAB-AGAR™
(Biocorp, Warsaw, Poland) (b)
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become increasingly prevalent. C. glabrata currently ranks
second as the causative agent of candidiasis in North
America and Europe. This changing epidemiology is associ-
ated with widespread use and prolonged prophylaxis of azole
antifungal agents in the growing population of high-risk pa-
tients. Despite C. glabrata lacks a number of virulence factors
(hyphal growth, ability to secrete proteases), it has enormous
adaptability to different host niches and intrinsically low sus-
ceptibility to azoles. Therefore, infections caused by these
yeasts are difficult to eradicate and associated with significant
mortality (Rodrigues et al. 2014; Kołaczkowska and
Kołaczkowski 2016).
C. glabrata is taxonomically classified to Nakaseomyces
clade together with three environmental species: C. castellii,
Nakaseomyces delphensis (syn. Kluyveromyces delphensis) and
Nakaseomyces bacillisporus (syn. Kluyveromyces bacillisporus)
(Kurtzman 2003). In the last decade, two new species,
C. nivariensis and C. bracarensis, isolated from samples taken
from patients with pathological conditions, were added to this
clade. These emerging pathogens have phenotypic characteristics
similar to those of C. glabrata, making them difficult to identify
by routine laboratory analysis. Conventional phenotypic-based
methods of identification, such as the Vitek 2 system, have prov-
en ineffective to differentiate isolates of C. glabrata complex
(Alcoba-Flórez et al. 2005; Correia et al. 2006; Hou et al.
2017), as was the case in the present study, where SU3498 isolate
was Bmisidentified^ as C. glabrata.
For the first time, C. nivariensis has been reported in a
Spanish hospital in 2005. The strains were isolated from
blood, bronchoalveolar lavage fluid (BALF) and urine of three
patients over a 3-year study period (Alcoba-Flórez et al.
2005). Current knowledge indicates that this species occurs
worldwide and the number of published cases reaches 108 in
Europe (Spain, the UK, France, Poland) (Borman et al. 2008;
Gorton et al. 2013; López-Soria et al. 2013; Parmeland et al.
2013; Swoboda-Kopeć et al. 2014; Aznar-Marin et al. 2016;
Angoulvant et al. 2016), 31 in Asia (Japan, Indonesia, India,
China, Malaysia) (Fujita et al. 2007; Wahyuningsih et al.
2008; Chowdhary et al. 2010; Sharma et al. 2013; Li et al.
2014; Tay et al. 2014; Feng et al. 2015; Hou et al. 2017), 11 in
Australia (Lockhart et al. 2009; Pinto et al. 2011), four in Latin
America (Argentina and Brazil) (Morales-López et al. 2016;
Figueiredo-Carvalho et al. 2016) and one case in Africa
(Burkina Faso) (Sanata et al. 2014).
Candida nivariensis was found to be uncommon among
clinical Candida isolates. Most studies have reported only
isolated clinical cases at medical centres.
Reports on large collections of yeast strains, acquired under
surveillance programmes, both national and global, have
shown a low prevalence of C. nivariensis of around 0.12%
(Angoulvant et al. 2016; Hou et al. 2017). To date, most iso-
lates of C. nivariensis have been reported from Europe, main-
ly France (68 cases), the UK (16) and Poland (13).
It is worth noting that C. nivariensis strains have not been
detected among 353 C. glabrata isolates obtained from pa-
tients hospitalised at the above mentioned four medical cen-
tres in Kraków, while Swoboda-Kopeć et al. have found 13
C. nivariensis isolates among 224 (5.8%) C. glabrata com-
plex strains collected from patients of the Warsaw Medical
University Clinical Hospital (Swoboda-Kopeć et al. 2014).
This is particularly significant, as these cities are only about
300 km from each other. However, Warsaw is the capital of
Poland and the population in this agglomeration is about three
times larger and more varied than that of Kraków. The volume
of commuting inWarsaw is also higher and international trade
and travel can potentially contribute to the occurrence of new
pathogens (Neiderud 2015).
The number of reported C. bracarensis isolates is even
lower than that of C. nivariensis. The first two strains were
isolated as the causative agent of a case of vulvovaginal can-
didiasis (Portugal, 2006) and from a blood culture in the UK in
2003 (Correia et al. 2006). To date, a total of 10C. bracarensis
strains have been isolated in Europe (Portugal, the UK,
France, Spain) (Correia et al. 2006; Cendejas-Bueno et al.
2010; Lacroix et al. 2014; Angoulvant et al. 2016), seven in
North America (USA and Canada) (Bishop et al. 2008;
Lockhart et al. 2009; Warren et al. 2010), two in Asia
(China) and two in Latin America (Argentina) (Li et al.
2014; Hou et al. 2017; Dudiuk et al. 2017). We have recently
isolatedC. bracarensis from the stool of a patient with periph-
eral neuropathy caused by diabetes mellitus. Although
C. nivariensis and C. bracarensis are reported as a part of
the commensal flora of the gastrointestinal or genitourinary
tract mucous membranes, the cases of fungaemia caused by
these species confirm their pathogenic significance to humans.
It should be noted that risk factors for invasive fungal infec-
tions, especially candidaemia, include also diabetes mellitus.
It is worth mentioning that the presence of C. nivariensis and
C. bracarensis strains was confirmed also in the environment.
The D1–D2 sequences of the first three Spanish C. nivariensis
isolates revealed a high level of similarity (99%) with the se-
quence of aCandida sp. AF313362 belonging to a strain isolated
by Lachance et al. (2001) from Hibiscus sp. flowers in the
Northern Territories (Canada). Eleven strains of C. nivariensis
have been also isolated from the phylloplane of sugarcane leaf in
Thailand (Limtong and Koowadjanakul 2012; Limtong et al.
2014). The analysed sequence of C. bracarensis strain described
in this study was identical to the uncultured fungus clone
CMH366 (GenBank accession number KF800457.1) isolated
from an environmental sample (air and dust) collected in the
homes of asthmatic children, located in Kansas City (Rittenour
et al. 2014). Candidiasis is most often an endogenous infection;
however, exogenous infections have been also reported.
Therefore, it can be assumed that C. nivariensis and
C. bracarensis distributed in the environment could be a potential
source of infections, especially in high-risk patients.
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Varying susceptibility of C. nivariensis and C. bracarensis
strains to antifungal agents is of particular concern. Several
isolates have been reported either resistant or with reduced
susceptibility to azoles or amphotericin B (Bishop et al.
2008; Lockhart et al. 2009). The C. bracarensis isolate de-
scribed in our study had itraconazole and posaconazole MICs
≥ 32 mg/L, and fluconazole MIC = 3 mg/L. Transfer of resis-
tance does not occur among yeasts and the acquisition of
resistance can be observed mainly in restricted clinical set-
tings, due to prolonged azole treatment. Therefore, species
identification is generally sufficient to predict their drug sus-
ceptibility (Cornet et al. 2011). Empirical therapy is a common
practice and the selection of antifungal agents is usually based
on prediction of the most likely pathogens and their suscepti-
bility patterns. Accurate identification of new species is be-
coming increasingly important for clinical management.
In the light of increasing frequency of isolation of cryptic
species belonging to theNakaseomyces clade from human sam-
ples, and decreased susceptibility to antifungals observed in
some isolates, further studies on geographical distribution of
C. nivariensis and C. bracarensis and clinical characterisation
of infections caused by these species are required. The true
incidence of C. nivariensis and C. bracarensis remains un-
known. Further isolates have been reported from different parts
of the world, indicating that these pathogens are widely distrib-
uted and play an important role in human infections. Published
data suggest that C. nivariensis and C. bracarensis seem to be
prevalent more locally. The best approach to the treatment of
Candida infections, ensuring patients’ best health outcomes, is
early detection and correct identification of the species in order
to administer appropriate antifungal therapy.
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